Page last updated: 2024-10-21

ethylisopropylamiloride and Leukemia

ethylisopropylamiloride has been researched along with Leukemia in 1 studies

ethylisopropylamiloride: structure in first source
ethylisopropylamiloride : A member of the class of pyrazines that is amiloride in which the amino substitutent of the pyrazine ring that is adjacent to the chloro substituent has been substituted by an ethyl group and by an isopropyl group.

Leukemia: A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Acevedo-Olvera, LF1
Diaz-Garcia, H1
Parra-Barrera, A1
Caceres-Perez, AA1
Gutierrez-Iglesias, G1
Rangel-Corona, R1
Caceres-Cortes, JR1

Other Studies

1 other study available for ethylisopropylamiloride and Leukemia

ArticleYear
Inhibition of the Na+/H+ antiporter induces cell death in TF-1 erythroleukemia cells stimulated by the stem cell factor.
    Cytokine, 2015, Volume: 75, Issue:1

    Topics: Amiloride; Apoptosis; Autophagy; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Separation;

2015